AQP4 and neuromyelitis optica: Satralizumab, Denosumab, and Brodalumab (Siliq) are monoclonal antibodies FDA-approved to treat anti-aquaporin-4 (AQP4) antibody-positive neuromyelitis optica spectrum disorder (NMOSD) [86,87], postmenopausal osteoporosis [88], and moderate to severe plaque psoriasis in adult patients [89], respectively.